DEXs generated by such mature DCs have shown the ability to induce greater T‐cell stimulation than DEXs from immature DCs.181, 182, 183 In a recent phase II clinical trial, such second generation DEXs (IFNγ‐DEX) were loaded with MHC‐I and MHC‐II‐restricted tumor antigens and administered as maintenance immunotherapy to patients bearing inoperable NSCLC tumors after induction chemotherapy.184 The IFNγ‐DEXs did not induce antigen‐specific T‐cell responses, but successfully boosted the NK cell antitumor immunity. Here, IFNG is linked to non-small cell lung carcinoma.